Alignment Healthcare, Inc. (ALHC), a technology-enabled Medicare Advantage insurer focused on senior healthcare, saw its stock plunge more than 8% in Thursday's session. The shares traded near $7.39, down from a prior closing price of $8.06, extending losses that followed Wednesday's after-hours earnings release. The immediate trigger was a third-quarter report that beat on revenue but exposed a sharp rise in medical costs, prompting management to slash full-year profitability guidance.
The primary catalyst behind the decline was the company's Q3 2026 report. Revenue grew roughly 37% year over year to about $1.36 billion, beating consensus estimates, and health plan membership climbed 31% to 301,200. However, the adjusted medical benefits ratio (MBR) rose to 89.5%, up about 240 basis points from a year earlier, reflecting higher provider appeals and disputes tied to a claims-system migration, along with elevated costs in skilled-nursing and catastrophic cases.
The profit reset proved more consequential than the top-line beat. Management cut full-year adjusted EBITDA guidance to at least $100 million, down sharply from a prior range of $145 million to $163 million, and reduced adjusted gross profit guidance to at least $575 million from $630 million to $650 million. Fourth-quarter guidance implied a further step-up in medical costs, signaling that the elevated claims environment is expected to persist into the year's end.
Compounding the selling pressure, KeyBanc downgraded ALHC to Sector Weight from Overweight. The firm cited reduced confidence in the company's 2027 EBITDA baseline given higher costs that developed during the third quarter, as well as limited visibility into the company's Star Ratings for the 2029 payment year.
Investors also weighed a structural concern: the company's largest contract, its California HMO plan, dropped to a 3.5 Star Rating for payment year 2028. Although six of seven eligible plans maintained four-star or better ratings, the California downgrade represents a meaningful revenue headwind tied to Alignment's most concentrated exposure. Management indicated it is pursuing Stars litigation and risk-adjustment improvements as partial offsets.
Trading volume was notably elevated as investors repriced the stock in the wake of the earnings reset, with Wednesday's session already showing a sharp spike in turnover versus the stock's recent average. The move was largely company-specific rather than a broad sector event, as the selloff diverged from the broader healthcare and managed-care complex. The shares traded well below key short-term moving averages, reflecting a technical breakdown as the market absorbed the lowered outlook.
Looking ahead, investors will focus on the company's execution during the Annual Enrollment Period and the initial read on 2027 membership when management provides updates in January. Alignment reiterated a 2027 top-line growth target of at least 20% and said early enrollment results are off to a strong start, but the path back to margin expansion remains a central question. Key risks include continued medical-cost pressure, the intensity of competition in Medicare Advantage, and the outcome of efforts to remediate the California Star Rating shortfall. Analysts will be watching for evidence that claims trends stabilized into September and October as management suggested, and whether corrective initiatives begin to show up in future results.
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Explore the page to see which strategies are currently leading the pack.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALHC saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 68 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 85%.
The Moving Average Convergence Divergence Histogram (MACD) for ALHC turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ALHC entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ALHC's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in 247 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ALHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (5.743) is slightly higher than the industry average of (3.520). P/E Ratio (36.700) is within average values for comparable stocks, (126.353). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.389) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ManagedHealthCare